Monopar receives HREC clearance in Australia for Phase 1 trial of MNPR-101-Lu in advanced cancers

Monopar Therapeutics

HREC clearance in Australia to commence Phase 1 therapeutic trial of MNPR-101-Lu (Lu-177 with anti-uPAR antibody).
Trial will enroll patients with advanced solid cancers, including triple negative breast and pancreatic cancer.
Preclinical data showed complete tumor elimination in human pancreatic cancer xenograft model after single injection.
MNPR-101-Lu is a therapeutic follow-on to the ongoing MNPR-101-Zr imaging and dosimetry trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.